EU regulator supports a label expansion of Novo Nordisk's diabetes drug to reflect its potential to lower the risk of conditions related to kidney disease in adults with Type 2 diabetes. Deutsche Bank ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback